Scientific article
Open access

Biomarkers of gemtuzumab ozogamicin response for acute myeloid leukemia treatment

Published inInternational journal of molecular sciences, vol. 21, no. 16, 5626
Publication date2020-08-06

Gemtuzumab ozogamicin (GO, Mylotarg®) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials, led to the Food and Drug Administration (FDA) approval on 1 September 2017 in CD33-positive AML patients aged 2 years and older. Discrepancies in GO recipients outcome have raised significant efforts to characterize biomarkers predictive of GO response and have refined the subset of patients that may strongly benefit from GO. Among them, CD33 expression levels, favorable cytogenetics (t(8;21), inv(16)/t(16;16), t(15;17)) and molecular alterations, such as NPM1, FLT3-internal tandem duplications and other signaling mutations, represent well-known candidates. Additionally, in depth analyses including minimal residual disease monitoring, stemness expression (LSC17 score), mutations or single nucleotide polymorphisms in GO pathway genes (CD33, ABCB1) and molecular-derived scores, such as the recently set up CD33_PGx6_Score, represent promising markers to enhance GO response prediction and improve patient management.

  • CD33
  • FLT3
  • Acute myeloid leukemia
  • Biomarkers
  • Gemtuzumab ozogamicin
  • Therapy
Affiliation Not a UNIGE publication
Citation (ISO format)
FENWARTH, Laurène et al. Biomarkers of gemtuzumab ozogamicin response for acute myeloid leukemia treatment. In: International journal of molecular sciences, 2020, vol. 21, n° 16, p. 5626. doi: 10.3390/ijms21165626
Main files (1)
Article (Published version)
ISSN of the journal1422-0067

Technical informations

Creation03/19/2024 9:40:41 AM
First validation05/23/2024 8:54:30 AM
Update time05/23/2024 8:54:30 AM
Status update05/23/2024 8:54:30 AM
Last indexation05/23/2024 8:54:51 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack